Recalculation of conversion price for Elekta’s convertible bond due to resolution to implement Elekta share split
On September 4, 2012, Elekta’s Annual General Meeting resolved on a split of the Company’s shares, whereby each existing share with a quotient value of SEK 2.00 will be divided into four new shares with a quotient value of SEK 0.50, without changing the Company’s share capital. The total number of shares prior to the split is 95,701,670, represented by 3,562,500 series A shares and 92,139,170 series B shares. Following the split, there will be 382,806,680 shares, represented by 14,250,000 series A shares and 368,556,680 series B shares. The record day for the split was set as September 14, 2012, assuming that the Swedish Companies Registration Office has registered the split by that date.
Due to Elekta’s share split, the conversion price for Elekta’s convertible bond has been recalculated. The new conversion price is SEK 97.50 (SEK 390 before recalculation). The recalculated conversion price will be applied after the record day, September 14, 2012, for conversions implemented following the resolution on the share split.
For further information, please contact:
Johan Andersson Melbi, Investor Relations Manager, Elekta AB
Tel: +46 702 100 451, e-mail: email@example.com
The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 11.00 CET on September 7, 2012.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb.